Skip to content
Screener

CG Oncology CGON Q3 2025 earnings

Reported November 14, 2025 · Before market open

Revenue$1.7MBeat by $1.6M
EPS-$0.57Miss by $0.01
Revenue estimate$59.4K
EPS estimate-$0.56

Next report

Nov 13, 2026 (in 2 months)
Revenue estimate$547.7K
EPS estimate-$0.86

Financials

Q3 2025

Income statement

See full
Revenue$1.7M+3,774%
Operating income-$51.1M-80.7%
Net income-$43.8M-115%
EPS (diluted)-$0.57-90.0%

Balance sheet

See full
Cash & equivalents$45.1M+4.0%
Total debt$7.2M+2,346%
Total equity$687.6M+28.1%
Total assets$729.9M+32.1%

Cash flow

See full
Operating cash flow-$38.9M-144%
CapEx$97.0K—
Free cash flow-$39.0M-145%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$3.07B+22.1%
Enterprise value$3.03B+22.7%
P/S1,412.7×-2,264×

Profitability

See full
Operating margin-8,285.3%-2,407pp
Net margin-6,968%-1,788pp
FCF margin-5,387.7%—

Returns & leverage

See full
Return on equity-24.7%—
Debt / equity0×0.0×
Current ratio22.8×-12.5×

Segments

By product

See full
Commercial And Development Revenue$1.5M—
License And Collaboration Revenue$158.0K+267%

FAQ

When did CG Oncology report Q3 2025 earnings?
CG Oncology (CGON) reported Q3 2025 earnings on November 14, 2025 before market open.
What were CG Oncology's Q3 2025 revenue and EPS?
CG Oncology reported revenue of $1.7M and eps of $-0.57 for Q3 2025.
Did CG Oncology beat estimates in Q3 2025?
Revenue beat the consensus estimate of $59.4K by $1.6M. EPS missed the consensus estimate of $-0.56 by $0.01.
Where can I find CG Oncology's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-283108) and the 10-Q periodic report (0001193125-25-283000) directly on SEC EDGAR. The filing index links above go to sec.gov.